Baxter International enters its July 30 earnings report in a curious position: short sellers have been retreating even as the stock climbs, but the analyst community remains divided on whether the recovery has legs.
Short interest is meaningful but moving in the bears' favor — not against them. At 7.5% of free float (roughly 38.5 million shares), the short position is real. Yet it has fallen nearly 9% over the past month, with the sharpest drop coming in early July when shares short fell from around 42 million to 38 million in a matter of days. Borrow costs are low at 0.54% and have eased slightly on the week. Availability is comfortable at 175% — nearly two shares available to borrow for every one currently lent out — well above the 52-week tightest level of 127%. The lending market is not squeezed; shorts have room to add if the print disappoints. Options traders are equally relaxed: the put/call ratio of 0.48 is almost exactly in line with its 20-day average, carrying a z-score near zero. Neither options nor borrow markets are flashing elevated anxiety.
The stock itself has been doing the work. BAX gained 3.4% on Friday and is up 11% over the past month, now trading at $22.40. That move has drawn fresh analyst attention. Goldman Sachs raised its target to $21 from $19 on July 15, maintaining Neutral — a modest acknowledgment of the recovery. Evercore ISI, carrying an Outperform, lifted its target to $24 from $22 earlier in July. Both moves signal that even cautious voices are adjusting upward. The consensus remains a Hold with a mean target of $21.95 — fractionally below the current price — which means the Street as a whole is not yet convinced the rally warrants chasing. Citigroup sits at Sell with a $17 target, and Morgan Stanley holds an Underweight; those two drag on the consensus. Bulls point to the Healthcare Systems & Technologies segment's steady mid-single-digit growth and the Hillrom acquisition's expanding portfolio. Bears cite the Q2 2025 miss — sales, margins, and EPS all fell short of expectations — and question whether manufacturing inefficiencies and an unfavorable product mix have been durably fixed.
Institutional ownership adds a contrasting thread. FMR (Fidelity) added roughly 6.7 million shares in the quarter to June 30, making it one of the more active buyers among the top holders. BlackRock added 504,600 shares across the same period. These are not distressed-seller flows; they suggest large passive and active managers are comfortable holding through the print. Insider activity, by contrast, skews negative — the CFO and multiple senior executives sold shares in early March, though at prices around $17-$19, well below where the stock trades today. Those sales may have been routine plan activity rather than a directional signal.
The earnings history adds one more data point: the two most recent prints produced positive one-day moves of roughly 2%, with five-day gains of 3-8%. The pattern is constructive, but the bar has risen — BAX now trades more than 25% above where it stood at the time of those releases. Wednesday's print will test whether the operational improvement that drove the recent re-rating is broad enough and durable enough to justify a stock that has, for the first time in months, moved ahead of analyst consensus.
See the live data behind this article on ORTEX.
Open BAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
